EURURO Vol. 72 No. 4

517 656

Prostate Cancer’’. Gemma Logan—employment at Almac Diagnostics.
Viktor Berge—honoraria (Astellas). Amir Sherif—none. Hardev Pandha—
none. Anne Warren—none. Catherine Davison—none. Jaine Blayney—
none. Bethanie Price—employment at Almac Diagnostics, patent or IP
‘‘Molecular Test for Prostate Cancer’’. Gera Jellema—employment at
Almac Diagnostics, patent or IP ‘‘Molecular Test for Prostate Cancer’’. Aud
Svindland—none. Simon McDade—none. Christopher Eden—travel and
expenses (Intuitive Surgical). Chris Foster—none. Ian Mills—research
funding (Johnson & Johnson). David Neal—employment at Elsevier,
stock/ownership (Relx), patent or IP (CRUK). Malcolm Mason—none.
Elaine Kay—consulting/advisory role (Almac Diagnostics). David
Waugh—consulting/advisory role (Almac Diagnostics. Paul Harkin—
employment at Almac Diagnostics, stock/ownership (Fusion Antibodies),
patent or IP ‘‘Molecular Test for Prostate Cancer’’. William Watson—
none. Noel Clarke—none. Richard Kennedy—employment at Almac
Diagnostics, research funding (Almac Diagnostics & QUB), patent or IP
‘‘Molecular Test for Prostate Cancer’’. Adam Uprichard–none. Employ-
ment Almac Diagnostics.
Funding/Support and role of the sponsor: This work was supported by
Almac Diagnostics, the Belfast-Manchester Movember Centre of Excel-
lence (CE013_2-004), funded in partnership with Prostate Cancer UK
(David J. Waugh, Noel W. Clarke, and Ian G. Mills) and by European
Regional Development Fund through Invest Northern Ireland (INI, Ref:
RD1208001 and RD0115336). The specific role of the funding organisa-
tion or sponsor is as follows: design and conduct of the study, and
collection of the data.
Acknowledgments: We acknowledge the Welsh Cancer Biobank/Cardiff
University Health, Irish Prostate Cancer Research Consortium Biobank,
the Northern Ireland Biobank, and the Prostate Biobank associated with
Oslo University Hospital along with their members of the tissue
acquisition teams. In particular, we thank E. Smith (University of Surrey)
and L. Spary (Welsh Cancer Bank) for the support in acquiring samples
and corresponding clinical data from the clinical sites. We would also
like to thank J. Fay (RCSI, Beaumont Hospital) for continued support and
guidance with pathology.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
.
References
[1] Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus
observation for localized prostate cancer. N Engl J Med
2012;367:203–13 .
[2] Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy
or watchful waiting in early prostate cancer. N Engl J Med
2014;370:932–42 .
[3] Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a
large active surveillance cohort of patients with prostate cancer. J
Clin Oncol 2015;33:272–7
.
[4] Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph
node dissection an adequate staging procedure for prostate
cancer? J Urol 2002;168:514–8.
discussion 518.
[5] Roach 3rd M, DeSilvio M, Lawton C, et al. Phase III trial comparing
whole-pelvic versus prostate-only radiotherapy and neoadjuvant
versus adjuvant combined androgen suppression: Radiation Ther-
apy Oncology Group 9413. J Clin Oncol 2003;21:1904–11.
[6] Abdollah F, Gandaglia G, Suardi N, et al. More extensive pelvic
lymph node dissection improves survival in patients with node-
positive prostate cancer. Eur Urol 2015;67:212–9.
.
[7] Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy
with short-term or long-term androgen deprivation in localised
prostate cancer (DART01/05 GICOR): a randomised, controlled,
phase 3 trial. Lancet Oncol 2015;16:320–7.
.
[8] James ND, SydesMR, Clarke NW, et al. Addition of docetaxel, zoledronic
acid, or both to first-line long-termhormone therapy in prostate cancer
(STAMPEDE): survival results from an adaptive, multiarm, multistage,
platform randomised controlled trial. Lancet 2016;387:1163–77.
.
[9] Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The
changing face of low-risk prostate cancer: trends in clinical pre-
sentation and primary management. J Clin Oncol 2004;22:2141–9.
[10] Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy
after radical prostatectomy for high-risk prostate cancer: long-
term results of a randomised controlled trial (EORTC trial
22911). Lancet 2012;380:2018–27.
[11]
.
[12] Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California,
San Francisco Cancer of the Prostate Risk Assessment score: a
straightforward and reliable preoperative predictor of disease re-
currence after radical prostatectomy. J Urol 2005;173:1938–42.
[13] Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straight-
forward tool for improved prediction of outcomes after radical
prostatectomy. Cancer 2011;117:5039–46.
[14] Khor LY, Bae K, Paulus R, et al. MDM2 and Ki-67 predict for distant
metastasis and mortality in men treated with radiotherapy and
androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol
2009;27:3177–84. .
[15] Cuzick J, Yang ZH, Fisher G, et al. Prognostic value of PTEN loss in
men with conservatively managed localised prostate cancer. Br J
Cancer 2013;108:2582–9. .
[16] Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an
RNA expression signature derived from cell cycle proliferation
genes in patients with prostate cancer: a retrospective study.
Lancet Oncol 2011;12:245–55.
[17] Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a
prostate cancer genomic classifier that predicts early metastasis
following radical prostatectomy. PLoS One 2013;8:e66855.
[18] Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to
predict prostate cancer aggressiveness in the context of Gleason
grade heterogeneity, tumor multifocality, and biopsy undersam-
pling. Eur Urol 2014;66:550–60.
[19] Shipitsin M, Small C, Choudhury S, et al. Identification of proteomic
biomarkers predicting prostate cancer aggressiveness and lethality
despite biopsy-sampling error. Br J Cancer 2014;111:1201–12.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 0 9 – 5 1 8 517